Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis
Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis
复制标题
DOI：
10.1080/13813455.2018.1499119
复制
发表时间：
2020-03-14
影响因子：
3
通讯作者：
Toraih, Eman A.
中科院分区：
文献类型：
--
作者：
Fawzy, Manal S.;Abu AlSel, Baraah T.;Toraih, Eman A.
背景：循环非编码RNA（ncRNA）与健康和疾病有关。本研究旨在评估microRNA-499 a（miR-499 a）及其选择的生物信息学预测伴侣long-ncRNA MALAT 1（metastasis-associated lung adenocarcinoma transcript 1）在糖尿病相关终末期肾病（ESRD）患者血清中的表达谱，并将其表达与患者的临床实验室数据相关联。受试者和方法：实时定量聚合酶链反应应用于糖尿病合并和不合并终末期肾病（n = 90）。结果如下：相对于没有ESRD的糖尿病患者，ESRD组的血清MALAT 1表达水平增加，中值（四分位数）为10.5（1.41-126.7）（p < .001）。然而，超过一半的ESRD患者的miR-499 a水平降低，中位数为0.96（0.13-3.14）。MALAT 1和miR-499 a表达水平在ESRD患者组中呈负相关。结论：MALAT 1表达上调和miR-499表达下调可能参与了糖尿病肾病相关的ESRD发病机制。需要进行功能验证研究以确认MALAT 1/miR-499 a的伙伴关系。
Background: Circulating non-coding RNAs (ncRNAs) have been implicated in health and disease. This study aimed to evaluate the serum expression profile of microRNA-499a (miR-499a) and its selected bioinformatically predicted partner long-ncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) in diabetes-related end-stage renal disease (ESRD) patients and to correlate the expressions with the patients' clinicolaboratory data. Subjects and methods: Real-time quantitative polymerase chain reaction was applied in diabetics with and without ESRD (n = 90 for each). Results: Serum MALAT1 expression levels were increased in the ESRD group relative to diabetics without ESRD with median (quartile) values of 10.5 (1.41-126.7) (p < .001). However, miR-499a levels were decreased in more than half of ESRD patients with a median of 0.96 (0.13-3.14). Both MALAT1 and miR-499a expression levels were inversely correlated in the ESRD patient-group. Conclusions: MALAT1 up-regulation and miR-499 down-regulation might be involved in diabetic nephropathy-related ESRD pathogenesis. Functional validation studies are warranted to confirm the MALAT1/miR-499a partnership.